While most individuals impacted by COVID-19 experience milder symptoms and recover within a few weeks, the global pandemic caused by the SARS-CoV-2 virus continues to pose a significant health challenge. Some of those affected may progress to develop more severe illness and pneumonia, often resulting in a more unfavorable prognosis.
Although protocols have been developed to assess patients' risk, diagnostic and prognostic tools primarily rely on expensive and less accessible imaging methods, such as radiography, ultrasound, or computed tomography (CT). Therefore, there is a need to develop a simpler and more readily available prognostic tool that enables healthcare providers to identify patients who have developed or are at risk of developing severe disease. This would streamline patient triage and facilitate early intervention, even in home or primary care settings.
Now, a research team led by IBEC and Hospital del Mar, with collaboration from the Universitat Politècnica de Catalunya (UPC), CIBER-BBN and CIBERES, has carried out a study based on the analysis and interpretation of cough sounds in the initial phases of COVID-19. This method is presented as a potential predictive, simple, and accessible tool to assess the risk of suffering severe pneumonia.
The research involved smartphone recordings of voluntary coughing sounds from 70 patients with SARS-CoV-2 infection, all recorded within the first 24 hours after their admission to the hospital. IBEC conducted an acoustic analysis of these recordings, which revealed significant differences in cough sounds depending on the severity of the respiratory condition, as previously confirmed by imaging tests and the need for supplemental oxygen. The results indicate that this analysis could be used to categorize COVID-19 patients as mild, moderate, or severe and to monitor patients with persistent COVID-19. The study was conducted using data collected between April 2020 and May 2021 at Hospital del Mar, and the findings have been published in the European Respiratory Journal Open Research.
Cough frequency: a key parameter
Raimon Jané, a professor at UPC and the principal investigator at IBEC and CIBER-BBN, leads the Biomedical Signal Processing and Interpretation (BIOSPIN) group at IBEC. This group has developed the methodology and algorithms for the acoustic analysis of cough signals collected via smartphones. Using a statistical model known as a linear mixed model, the team identified five parameters, based on sound frequencies, that exhibited significant differences in the coughs of patients with varying levels of disease severity and pneumonia progression. These differences may reflect the progressive respiratory system alterations in patients with COVID-19
While acoustic cough analysis methods have been previously proposed for diagnosing respiratory diseases, we aimed to take a step further by specifically investigating the connection between the acoustic characteristics of coughs and the varying levels of pneumonia severity in COVID-19 patients," details Jané, the senior co-author of the study.
The authors of the study explain that cough analysis can serve a dual purpose: early detection of severe COVID-19 cases and remote monitoring of their progression, including the assessment of potential complications. However, further research involving a larger patient sample will be required to validate the findings of this cross-sectional study, which could pave the way for utilizing cough analysis as a diagnostic tool for patients with COVID-19 and other respiratory diseases.
For this reason, Dr. Joaquim Gea, emeritus head of the Pneumology Service, researcher at the Hospital del Mar Research Institute, and senior co-author of the study, suggests that these findings can prove beneficial “in regions with limited medical infrastructure or during emergency situations. This approach can aid in the prompt identification and isolation of COVID-19 patients, thus facilitating proper medical care and the implementation of control measures.”
Another noteworthy aspect is that, while the study primarily centered on COVID-19, it paves the way for applying this model to other respiratory conditions.
Journal
European Respiratory Journal
Method of Research
Computational simulation/modeling
Subject of Research
People
Article Title
Differences in acoustic features of cough by pneumonia severity in patients with COVID-19: a cross-sectional study.
Article Publication Date
2-May-2023
COI Statement
C. Davidson declares receipt of a BEST postdoctoral fellowship funded by the European Commission under Horizon 2020’s Marie Skłodowska-Curie Actions COFUND scheme (GA 712754) and the Severo Ochoa programme of the Spanish Ministry of Science and Competitiveness (SEV-2014-0425 (2015–2019); and funding from the Spanish Ministry of Science, Innovation and Universities under Grant RTI2018-098472-B-I00 MCIU/ AEI/FEDER. O.A. Caguana declares payment or honoraria to them and their institution from GlaxoSmithKline, AstraZeneca, Menarini and FAES, and to their institution alone from Chiesi, and support for attending meetings and/or travel from Chiesi, FAES and Menarini. I. Ferrer-Lluis declares funding for the present study from La Caixa INPhINIT grant LCF/BQ/DI17/11620029, the European Union Horizon 2020 Research and Innovation Program (grant number 713673), the Spanish Ministry of Science, Innovation and Universities (grant RTI2018-098472-B-I00 MCIU/ AEI/FEDER), and CIBER-BBN (mobility grant 2019 CB06/01/1050). Y. Castillo-Escario declares funding for the present study as follows from La Caixa Foundation (ID 100010434; fellowship code LCF/BQ/DE18/11670019), Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) contract “PREDOCTORAL LEY DE LA CIENCIA”, and the Spanish Ministry of Science, Innovation and Universities and European Regional Development Fund (Grant RTI2018-098472-B-I00), as well as receipt of a travel grant from CIBER-BBN. P. Ausín declares payment or honoraria to them and their institution from Sanofi, GlaxoSmithKline, AstraZeneca and Menarini, and to their institution alone from Chiesi, and payment for expert testimony from AstraZeneca, support for attending meetings and/or travel from GlaxoSmithKline and Sanofi, and participation on a Data Safety Monitoring Board or Advisory Board for Sanofi, all in the 36 months prior to manuscript submission. J. Gea declares grants or contracts from SEPAR, FIS (ISCiii) and EC, and the Horizon Programme of the European Union, and consulting fees from GlaxoSmithKline and Menarini, all in the 36 months prior to manuscript submission. R. Jané declares funding for the present study paid to their institution from the Spanish Ministry of Science, Innovation and Universities under grant RTI2018-098472-B-I00 MCIU/AEI/FEDER (Spain). All other authors declare no competing interests.